^
    2d
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    2d
    KEYNOTE-A72: A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=169, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    2d
    ARC-10: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (clinicaltrials.gov)
    P2, N=169, Active, not recruiting, Arcus Biosciences, Inc. | Phase classification: P3 --> P2 | Trial primary completion date: Aug 2024 --> May 2027
    Phase classification • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3d
    GALAXIES LUNG-201: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer (clinicaltrials.gov)
    P2, N=340, Recruiting, GlaxoSmithKline | Trial completion date: Jan 2028 --> Oct 2028
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    7d
    Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (clinicaltrials.gov)
    P2, N=255, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    docetaxel • vibostolimab/pembrolizumab (MK-7684A)
    11d
    SKYSCRAPER-09: A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P2, N=123, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Feb 2025
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    11d
    SKYSCRAPER-15: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (clinicaltrials.gov)
    P3, N=56, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | N=1150 --> 56 | Trial completion date: Jun 2039 --> Dec 2025 | Trial primary completion date: Mar 2034 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    15d
    Phase 2 randomized study of domvanalimab combined with zimberelimab in front-line, PD-(L)1 high, locally advanced or metastatic non-small cell lung cancer (NSCLC): results from ARC-10 part 1 (SITC 2024)
    Ethics Approval At each site, the study was conducted in full accordance with the 21 Code of Federal Regulations, International Council for Harmonisation guidelines, institutional review board and independent ethics committee guidelines, and all other applicable local or regional regulations. All patients provided written informed consent before enrollment.View this table:View inline View popup Download powerpoint Abstract 1461 Table 1 ARC-10 study efficacy endpointsDownload figure Open in new tab Download powerpoint Abstract 1461 Figure 1 Kaplan-Meier estimate of progression-free survivalDownload figure Open in new tab Download powerpoint Abstract 1461 Figure 2 Kaplan-Meier estimate of overall survival
    Clinical • P2 data • Late-breaking abstract • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    16d
    Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (clinicaltrials.gov)
    P3, N=1264, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2028 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
    18d
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (clinicaltrials.gov)
    P1/2, N=53, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    18d
    Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=16, Terminated, iTeos Therapeutics | Phase classification: P1/2 --> P1
    Phase classification • Combination therapy
    |
    dexamethasone • iberdomide (CC-220) • belrestotug (EOS-448)
    1m
    Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=258, Not yet recruiting, Sichuan Huiyu Pharmaceutical Co., Ltd
    New P1/2 trial • Metastases
    1m
    Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (clinicaltrials.gov)
    P3, N=1246, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
    1m
    Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • oxaliplatin • tiragolumab (RG6058) • fluorouracil topical
    1m
    An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma (clinicaltrials.gov)
    P1/2, N=40, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (RG6058)
    1m
    Association of biomarkers with response to vibostolimab coformulated with pembrolizumab in 2 cohorts of the phase 2 KEYVIBE-005 study (SITC 2024)
    Background In the multicohort phase 2 KEYVIBE-005 study (NCT05007106), the antitumor activity of vibostolimab (anti-T-cell immunoreceptor with Ig and ITIM domains [TIGIT]) coformulated with pembrolizumab (anti–PD-1; vibostolimab/pembrolizumab) was demonstrated in patients with previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer (cohort B1; n = 40; ORR, 64%) and in patients with previously untreated advanced esophageal cancer treated with vibostolimab/pembrolizumab plus 5-fluorouracil and cisplatin (cohort E; n = 40; ORR, 53%). Ethics Approval The study protocol and all amendments were approved by the institutional review board or ethics committee at each institution. Consent All patients provided written informed consent.
    P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
    1m
    ARTEMIDE-Lung03: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (clinicaltrials.gov)
    P3, N=878, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • rilvegostomig (AZD2936)
    1m
    An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated due to Sponsor decision.
    Trial termination
    |
    Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Lunsumio (mosunetuzumab-axgb)
    1m
    INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. (PubMed, Cancer Immunol Immunother)
    Delivering PH-804 to NK cells before ACT has emerged as a promising strategy to counter TIGIT inhibition, thereby improving the antitumor response. This approach offers the potential for more potent off-the-shelf products for adoptive cell therapy, particularly for hematological malignancies.
    Journal • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    TIGIT expression
    |
    PH-804 TME
    1m
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Sep 2024 --> May 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    2ms
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=410, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Aug 2024 --> Apr 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)
    2ms
    Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (clinicaltrials.gov)
    P1/2, N=86, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    TNFA (Tumor Necrosis Factor-Alpha) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    SMARCA4 mutation
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    AdvanTIG-205: Ociperlimab with Tislelizumab and Chemotherapy in Participants with Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=272, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    2ms
    Development and characterisation of [18F]TTDP, a novel T cell immunoglobulin and ITIM domain tracer, in humanised mice and non-human primates. (PubMed, Eur J Nucl Med Mol Imaging)
    The combined implementation of the [18F]TTDP and HIS-PDX model creates a state-of-the-art preclinical platform that will impact the identification and validation of TIGIT-targeted PET image-guided diagnosis, treatment response prediction, beneficial patient screening, novel immunotherapies, and ultimately the outcome of NSCLC patients. We first provided in vivo biodistribution of [18F]TTDP PET imaging in rhesus macaque, indicating its excellent translational potential in the clinic.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    TIGIT expression
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    First-In-Human Study of EOS884448 in Participants with Advanced Cancers. (clinicaltrials.gov)
    P1, N=40, Completed, iTeos Therapeutics | Phase classification: P1/2 --> P1
    Phase classification
    |
    belrestotug (EOS-448)
    2ms
    Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (clinicaltrials.gov)
    P2, N=255, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2027 --> Oct 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    docetaxel • vibostolimab/pembrolizumab (MK-7684A)
    2ms
    DESTINY-BTC01: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (clinicaltrials.gov)
    P3, N=620, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)
    2ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, BeiGene | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    2ms
    Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). (clinicaltrials.gov)
    P2, N=29, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • tiragolumab (RG6058)
    2ms
    A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    vibostolimab/pembrolizumab (MK-7684A)
    2ms
    AdvanTIG-105: Study of Ociperlimab (BGB-A1217) in Combination with Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=449, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    2ms
    The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies. (PubMed, Future Oncol)
    These studies will also evaluate coformulated immunotherapy addressing issues that occur with the sequential administration of immunotherapy. The KEYVIBE program will provide further insight into the clinical utility of vibostolimab-based therapy across multiple indications and various stages of disease.
    Journal • Metastases
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Keytruda (pembrolizumab) • vibostolimab (MK-7684)
    2ms
    A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • BNT327
    3ms
    Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=10, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    3ms
    A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) (clinicaltrials.gov)
    P1/2, N=12, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=90 --> 12
    Trial completion • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • tiragolumab (RG6058)
    3ms
    NEOLANGIO: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, University Health Network, Toronto
    New P2 trial
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • rilvegostomig (AZD2936)
    3ms
    TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov)
    P3, N=660, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy • Circulating tumor DNA
    |
    cisplatin • carboplatin • pemetrexed • etoposide IV • vinorelbine tartrate • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936)
    3ms
    A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=25, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Apr 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    3ms
    Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P2 trial • Metastases
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • ZG005
    3ms
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=792, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3ms
    A Study of AK130 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=19, Completed, Akeso | Not yet recruiting --> Completed | N=72 --> 19 | Trial completion date: Jan 2025 --> May 2024
    Trial completion • Enrollment change • Trial completion date • Metastases
    3ms
    Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor (clinicaltrials.gov)
    P2, N=46, Completed, SCRI Development Innovations, LLC | Active, not recruiting --> Completed | N=80 --> 46
    Trial completion • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)